"The big randomized clinical trial is an 'endangered species,'" according to the senior author (from Johns Hopkins) of a recent study that charted a decline in clinical trials funded by the NIH. "Everyone wants an answer in a hurry."
The NIH budget has been flat, but costs to run a clinical trial have increased, and decreased buying power has resulted in fewer trials funded.
On one side, the argument is simply that we need to "come back to our senses" and increase funding.
On the other side, smaller, more focused trials may be "a positive trend" in the emerging era of personalized health care tailored to an individual's DNA.
Today's Wall Street Journal article:
LINKPost Edited (NKinney) : 5/29/2018 2:58:49 PM (GMT-6)